ASH 2023 | BGB-16673, a novel BTK degrader, in patients with R/R B-cell malignancies
John Seymour, MBBS, FRACP, PhD, Peter MacCallum Cancer Centre, East Melbourne, Australia, discusses a Phase I trial (NCT05006716) investigating BGB-16673, a novel BTK degrader, in patients with relapsed/refractory (R/R) B-cell malignancies. Early findings reveal a well-tolerated safety profile, positive clinical responses, and suggest the potential of this compound to overcome resistance to existing BTK inhibitors. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: AstraZeneca, AbbVie, Beigene, BMS, Gilead, Hoffmann-La Roche, Janssen; Membership on an entity’s Board of Directors or advisory committees: AstraZeneca, AbbVie, Beigene, Genor Bio, BMS, Gilead, Hoffmann-La Roche, Janssen; Research Funding: AbbVie, F. Hoffmann-La Roche Ltd; Speakers Bureau: AbbVie, Beigene, Hoffmann-La Roche; Consultancy: TG Therapeutics, BMS, Hoffmann-La Roche.
